Start Your Search
P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
P1.01-84 - High Basal Serum EGF Levels Predicts Response to CIMAvax-EGF, a Therapeutic Vaccine for Advanced NSCLC (ID 14045)
16:45 - 18:00 | Author(s): Patricia Luaces
CIMAvax-EGF is a therapeutic vaccine for the treament of advanced NSCLC. The rationale of its use is to create an immune response against circulating plasmatic EGF and by doing this prevent its binding to EGFR. Previous early stage trials have shown its safety and efficacy. Recently a randomized controlled phase III pivotal trial have confirmed its efficacy and safety in open population when used according to stablished protocols. Exploratory results from this study suggested EGF could function as prognostic and predictive biomarker. In this study we aim to evaluate whether basal EGF plasmatic levels can predict patients response to this immunotherapeutic product.
To know the effect of biomarker status on CIMAvax-effect we pooled data from two previously published controlled trials that used the product in a population of advanced non small cell lung cancer after First Line platinum based chemotherapy. Low doses of cyclophosphamide (200mg/m2) were administered IV three days before the first administration of the vaccine. 2.4 mg/dose of the product were administered during induction phase and then monthly for maintenance treatment. Both studies used Best Support Care as Control Arm. The main outcome was Overall Survival.4c3880bb027f159e801041b1021e88e8 Result
Out of 485 patients included in both studies, 229 were screening for EGF levels (56.5%), (120 and 109 in the high and low level subgroup, respectively). All patients were considered in the analyses. A significant biomarker/treatment effect was found (p=0.000). Hazard ratio (CIMAvax-EGF vs BSC) in the high egf subgroup favoured CIMAvax-EGF (0.44, p=0.000).
Basal level of plasmatic EGF predicts clinical benefit from CIMAvax-EGF therapeutic cancer vaccine in advanced NSCLC after First Line of Treatment based on Platinum. Vaccinated patients in the subgroup of high EGF levels significantly benefit from CIMAvax-EGF.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.